Liver in lipoprotein metabolism.
Explore the source record for details and available documents.
Cholesterol↗
Biomedical subjects
A Shahid
Publications and source records attributed to A Shahid.
Effect of meal on intragastric pH in patients with duodenal ulcer.
Explore the source record for details and available documents.
Condiments↗
Serum pepsinogen, a genetic marker in duodenal ulcer.
Explore the source record for details and available documents.
Duodenal Ulcer↗
Portal systemic encephalopathy (PSE).
Explore the source record for details and available documents.
Female↗
Choice of diuretics in cirrhosis with ascites.
Explore the source record for details and available documents.
Ascites↗
Electrolytes derangement in portal systemic encephalopathy (a preliminary study).
Explore the source record for details and available documents.
Hepatic Encephalopathy↗
Urinary protein in healthy subjects.
Explore the source record for details and available documents.
Adolescent↗
Disorders of renal function in hepatic coma.
Explore the source record for details and available documents.
Hepatic Encephalopathy↗
Ammonia intoxication in hepatic coma.
Explore the source record for details and available documents.
Ammonia↗
Nutritional aspects of hepatic coma.
Explore the source record for details and available documents.
Adolescent↗
Electrolytes in liver disease--a preliminary study.
Explore the source record for details and available documents.
Electrolytes↗
Electrolytes in healthy subjects.
Explore the source record for details and available documents.
Adolescent↗
Propranolol in psychiatric illness.
Explore the source record for details and available documents.
Anxiety Disorders↗
Bioavailability of intramuscular versus oral haloperidol in schizophrenic patients.
Explore the source record for details and available documents.
Absorption↗
Fluphenazine pharmacokinetics and therapeutic response.
We conducted a double-blind study of therapeutic outcome versus mean steady-state levels in 29 newly admitted schizophrenic and schizoaffective patients who were treated with a constant dose of fluphenazine HCI over a 2-week period. both an upper and lower end of the therapeutic window were suggested by three nonresponders whose plasma levels were above 2.8 ng per ml and by two nonresponders and one partial responder whose plasma levels were below 0.2 ng per ml. The mean terminal half-life of fluphenazine (+ or - SD) was 16.4 + or - 13.3 h. We found that concomitant use of benztropn mesylate during the initial 4 weeks of fluphenazine treatment did not significantly alter fluphenazine plasma levels.
Acetylation↗